Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Broadcom
AVGO
|
+$406M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$351M |
| 3 |
Meta Platforms (Facebook)
META
|
+$316M |
| 4 |
Walmart
WMT
|
+$230M |
| 5 |
ServiceNow
NOW
|
+$217M |
Top Sells
| 1 |
Apple
AAPL
|
+$549M |
| 2 |
Palantir
PLTR
|
+$549M |
| 3 |
Netflix
NFLX
|
+$378M |
| 4 |
NVIDIA
NVDA
|
+$267M |
| 5 |
Alibaba
BABA
|
+$207M |
Sector Composition
| 1 | Technology | 17.41% |
| 2 | Healthcare | 14.96% |
| 3 | Consumer Discretionary | 11.86% |
| 4 | Financials | 11.03% |
| 5 | Industrials | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Vanguard Consumer Discretionary ETF
VCR
$6.58B
| $2.02M | ﹤0.01% |
6,200
+5,000
| +417% | +$1.63M |
|
|
GRP.U
2002
Granite Real Estate Investment Trust
GRP.U
$3.43B
| $2.02M | ﹤0.01% |
43,100
-500
| -1% | -$23.4K |
|
2003
RXO
RXO
$2.71B
| $2.01M | ﹤0.01% |
105,400
-211,000
| -67% | -$4.03M |
|
2004
Vanguard Total International Stock ETF
VXUS
$104B
| $2.01M | ﹤0.01% |
32,300
+20,600
| +176% | +$1.28M |
|
2005
Five Point Holdings
FPH
$417M
| $2.01M | ﹤0.01% |
375,500
+1,600
| +0.4% | +$8.54K |
|
2006
Helios Technologies
HLIO
$1.8B
| $2M | ﹤0.01% |
62,475
+38,300
| +158% | +$1.23M |
|
2007
iShares Europe ETF
IEV
$2.34B
| $2M | ﹤0.01% |
34,300
+4,300
| +14% | +$250K |
|
|
VRE
2008
Veris Residential
VRE
$1.49B
| $1.99M | ﹤0.01% |
+117,800
| New | +$1.99M |
|
2009
Cidara Therapeutics
CDTX
$1.66B
| $1.99M | ﹤0.01% |
92,517
-3,100
| -3% | -$66.8K |
|
2010
Apple Hospitality REIT
APLE
$2.98B
| $1.98M | ﹤0.01% |
+153,600
| New | +$1.98M |
|
2011
NewMarket
NEU
$7.87B
| $1.98M | ﹤0.01% |
3,500
-1,600
| -31% | -$906K |
|
2012
Flexible Solutions
FSI
$123M
| $1.97M | ﹤0.01% |
390,645
+1,200
| +0.3% | +$6.06K |
|
|
PHLT
2013
Performant Healthcare, Inc. Common Stock
PHLT
$607M
| $1.97M | ﹤0.01% |
666,363
-36,500
| -5% | -$108K |
|
2014
Middleby
MIDD
$6.82B
| $1.97M | ﹤0.01% |
+12,970
| New | +$1.97M |
|
2015
Kodiak Sciences
KOD
$489M
| $1.97M | ﹤0.01% |
702,600
+241,000
| +52% | +$676K |
|
2016
Hanover Insurance
THG
$6.45B
| $1.97M | ﹤0.01% |
+11,300
| New | +$1.97M |
|
2017
Vanguard Russell 1000 ETF
VONE
$6.78B
| $1.95M | ﹤0.01% |
7,700
-9,600
| -55% | -$2.44M |
|
2018
Invesco S&P 500 Pure Value ETF
RPV
$1.37B
| $1.94M | ﹤0.01% |
21,000
+8,200
| +64% | +$757K |
|
2019
Marcus & Millichap
MMI
$1.26B
| $1.94M | ﹤0.01% |
+56,253
| New | +$1.94M |
|
2020
Zumiez
ZUMZ
$347M
| $1.94M | ﹤0.01% |
130,000
+76,189
| +142% | +$1.13M |
|
|
LSEA
2021
DELISTED
Landsea Homes
LSEA
| $1.93M | ﹤0.01% |
300,513
+19,400
| +7% | +$125K |
|
2022
SPDR S&P Global Natural Resources ETF
GNR
$3.32B
| $1.93M | ﹤0.01% |
36,200
-14,400
| -28% | -$767K |
|
|
CHMI
2023
Cherry Hill Mortgage Investment Corp
CHMI
$107M
| $1.93M | ﹤0.01% |
583,584
+35,800
| +7% | +$118K |
|
2024
Corsair Gaming
CRSR
$948M
| $1.92M | ﹤0.01% |
217,070
-36,666
| -14% | -$325K |
|
2025
Neuropace
NPCE
$326M
| $1.91M | ﹤0.01% |
155,800
+69,500
| +81% | +$854K |
|